Navigation Links
AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia
Date:3/6/2009

ificant long-term revenue for the Company while building value for our shareholders," said Juergen Engel, Ph.D., President and CEO of AEterna Zentaris.

About the Phase 3 Program with Cetrorelix in BPH

Cetrorelix pamoate is currently in three Phase 3 trials involving more than 1,600 patients with symptomatic BPH in Canada, the United States and Europe.

The first multi-center efficacy study for which patient recruitment was completed in April 2008, is currently being conducted primarily in the United States and Canada, with additional sites in Europe and involves 667 patients under the supervision of lead investigator, Herbert Lepor, MD, Professor at NYU School of Medicine, New York. Patients enter a 4-week run-in no-treatment observation period to confirm severity and stability of voiding symptoms based on the International Prostate Symptom Score (IPSS). Patients are then randomly allocated to cetrorelix or placebo in a double-blind fashion. Patients are administered cetrorelix by intra-muscular (IM) injection at Week 0, 2, 26 and 28 and are followed up to Week 52. Then, in an open-label extension, patients receive cetrorelix by IM injection at Week 52, 54, 78 and 80 and are followed up to Week 90.

The second multi-center Phase 3 efficacy study for which patient recruitment was completed in October 2008, involves 420 patients, mainly in Europe. Patients in this randomized placebo-controlled study with open-label extension conducted under the supervision of lead investigator, Prof. Frans M.J. Debruyne, MD, of the Andros Mannenkliniek, Arnhem, The Netherlands, receive cetrorelix according to similar dosing regimens used in the first study.

The primary endpoint for both North American and European efficacy studies is absolute change in IPSS between baseline and Week 52. Other efficacy endpoints include additional measures of BPH symptom progression and the need for BPH-related surgery. Safety endpoints include ch
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. AEterna Zentaris to Present at Upcoming RBC Capital Markets Healthcare Conference
2. AEterna Zentaris Closes Sale of Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
3. AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results
4. AEterna Zentaris to Announce Third Quarter 2008 Financial and Operating Results on November 13, 2008
5. AEterna Zentaris Agrees to Sell Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
6. AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108
7. AEterna Zentaris to Present at Upcoming Oppenheimer 19th Annual Healthcare Conference
8. AEterna Zentaris Receives Notification from Nasdaq Relating to Minimum Bid Price
9. AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
10. AEterna Zentaris to Present at BioContact Quebec on October 2, 2008
11. AEterna Zentaris to Present at Upcoming CIBC World Markets 7th Annual Eastern Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... San Francisco, CA (PRWEB) April 16, 2015 ... is scheduled to report first quarter results on Thursday, ... the announcement, Cytokinetics’ senior management will host a conference ... and financial results and the company’s outlook for the ... and can be accessed from the homepage and in ...
(Date:4/16/2015)... , April 16, 2015  Schulman Associates IRB, ... technology, has signed a long-term lease on Laboratory Drive ... North Carolina . The location will house review ... to provide high quality reviews and customer service to ... represented Schulman in the deal, while Capital ...
(Date:4/16/2015)... N.C. (PRWEB) April 16, 2015 ... Carolina at Charlotte (UNC Charlotte) spin-out company, announced ... L. Cooper, Ph.D., M.D., as Chief Operating Officer ... years of experience in developing clinical diagnostic and ... and infectious disease. , Cooper’s extensive career transcends ...
(Date:4/16/2015)... , April 16, 2015 /PRNewswire/ - Portage Biotech ... Canadian Securities Exchange: PBT.U), is pleased to announce that ... Show on April 25, 2015 to be held in ... Gregory Bailey and Mr. James Mellon ... and an update on the key programs at its ...
Breaking Biology Technology:Cytokinetics to Announce First Quarter Results on April 30, 2015 2Cytokinetics to Announce First Quarter Results on April 30, 2015 3Schulman IRB to Open Office in Research Triangle Park, N.C. 2OncoTAb Names Dr. David L. Cooper as COO 2Portage to Present at Master Investor 2015 in London, UK 2Portage to Present at Master Investor 2015 in London, UK 3Portage to Present at Master Investor 2015 in London, UK 4
... Laboratories, L.C., a,privately-owned biotechnology company, today announced ... the Company as Vice President and Chief,Medical ... as Professor of Medicine, Chief of,Hepatology and ... Stanford,University Medical Center. He is a past-president ...
... Jan. 4 Anadys Pharmaceuticals,Inc. (Nasdaq: ANDS ) ... Annual,JPMorgan Healthcare Conference on Thursday, January 10, 2008 at ... held at the Westin St. Francis,Hotel in San Francisco., ... of Anadys,Pharmaceuticals, Inc., will present an update and overview ...
... Jan. 4 ARCA Discovery Inc., a privately ... and other cardiovascular diseases, today announced Richard B.,Brewer, ... the 26th,Annual JPMorgan Healthcare Conference on Tuesday, January ... Healthcare Conference will be held January 7-10, 2008 ...
Cached Biology Technology:Romark Laboratories Names Emmet B. Keeffe, M.D. Vice President and Chief Medical Officer 2Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference 2ARCA Discovery, Inc. to Present at 26th Annual JPMorgan Healthcare Conference on January 8, 2008 2
(Date:4/14/2015)... April 14, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces ... the 2015 New York Design Awards under the category  ... York City Design Awards are part of a global ... 2,500 ratings from the marketplace, industry and judging panel. ...
(Date:4/10/2015)... 2015 Research and Markets ( ... "Security Competitive Profiles - NEC" report to their ... NEC will continue to supply a range of IT ... a company focus on the development of a Big ... opportunities in the Asia-Pacific region ...
(Date:4/6/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... focused on the growing mobile commerce market, announced ... for MINIATURE, MULTI-PURPOSE ANTENNA METHOD AND SYSTEM ... NXT-ID introduces a new revolutionary method and system ... use of miniature antenna modules for multiple purposes ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3NEC Security Competitive Profile 2015 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4
... New Orleans, LA LSU Health Sciences Center New ... years by the National Center for Research Resources (NCRR), ... This Center of Biological Research Excellence (COBRE) grant funds ... enabling them to successfully compete nationally for research funding. ...
... more soot for the amount of fuel used than other ... as much soot as previously estimated, according to the first ... and the University of Colorado conducted the study and present ... Geophysical Research Letters . The primary sources ...
... in the current issue of the journal , Environmental ... in sea spray, attacks and damages DNA in the ... body,s way of ,disposing the toxin inadvertently converts it ... brevetoxins produced by the red tide ,organism, Karenia ...
Cached Biology News:LSUHSC awarded $10M+ COBRE grant 2LSUHSC awarded $10M+ COBRE grant 3LSUHSC awarded $10M+ COBRE grant 4NOAA takes first broad look at soot from ships 2Aerosol toxins from red tides may cause long-term health threat 2
... Convenient platform for tube handling and reagent dispensing ... tubes - 96 x 0.3ml U-bottom ... - Thermo-Fast® 96 Non-Skirted Plate - ... x 0.5ml Thermo-Tubes Multiple workstations can be securely stacked ...
... well Magnetic-Ring Stand is designed for paramagnetic ... microplates. The stand has a plastic base ... plate footprint. The use of 96 extremely ... easy magnetic separation. With this magnetic stand, ...
... • Enzyme concentration - 5 units/µL ,• ... higher yields ,• Leaves an 'A' overhang ... polymerase which exhibits very high activity in ... To ensure the quality of the enzyme, ...
Taq DNA Polymerase (T. aquaticus), 250 units. For PCR and other procedures requiring DNA polymerase activity at elevated temperatures. Category: Nucleotides & Enzymes & Biochemicals, Modifying Enzyme...
Biology Products: